Health ❯ Healthcare ❯ Pharmaceuticals

Drug Approvals

FDA Approvals NHS Spending Revumenib Pembrolizumab Belzutifan and Pembrolizumab Inluriyo Market Competition Targeted Therapies Combination Therapies Vaping Deflazacort Tablets Clinical Guidelines Lecanemab Kisunla Wegovy Belzutifan Novo Nordisk Niacin Extended-Release Tablets Libtayo Approval Cancer Treatments Pfizer Inc. Eli Lilly Eylea HD

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

Regulators cited LITESPARK-022 results showing reduced recurrence risk, with specific dosing and safety guidance issued.

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC